CHOP chemotherapy plus rituximab compared with CHOP alone in diffuse large B-cell lymphoma patients

被引:0
|
作者
Poddubnaya, I [1 ]
Osmanov, D [1 ]
Babicheva, L [1 ]
Falaleeva, N [1 ]
机构
[1] NN Blokhin Canc Res Ctr, Moscow, Russia
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
478
引用
收藏
页码:177 / 177
页数:1
相关论文
共 50 条
  • [31] Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy
    Decker, Michael
    Rothermundt, Christian
    Hollander, Georg
    Tichelli, Andre
    Rochlitz, Christoph
    LANCET ONCOLOGY, 2006, 7 (08): : 693 - 694
  • [32] Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
    Ruan, Jia
    Martin, Peter
    Furman, Richard R.
    Lee, Shing M.
    Cheung, Ken
    Vose, Julie M.
    LaCasce, Ann
    Morrison, Julia
    Elstrom, Rebecca
    Ely, Scott
    Chadburn, Amy
    Cesarman, Ethel
    Coleman, Morton
    Leonard, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) : 690 - 697
  • [33] Rituximab plus CHOP for diffuse large-B-cell lymphoma. Reply
    Coiffier, B
    Gisselbrecht, C
    Reyes, F
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23): : 1831 - 1831
  • [34] Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma.: An update of the GELA study.
    Coiffier, B
    Fermé, C
    Hermine, O
    Haioun, C
    Baumelou, E
    Solal-Celigny, P
    Delmer, A
    Sebban, C
    Mounier, N
    Tertian, G
    Van Hoof, A
    Bosly, A
    BLOOD, 2001, 98 (11) : 725A - 725A
  • [35] Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
    Ennishi, D.
    Asai, H.
    Maeda, Y.
    Shinagawa, K.
    Ikeda, K.
    Yokoyama, M.
    Terui, Y.
    Takeuchi, K.
    Yoshino, T.
    Matsuo, K.
    Hatake, K.
    Tanimoto, M.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1217 - 1221
  • [36] A pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
    Micallef, INM
    Kahl, BS
    Gayko, U
    Cesano, A
    Ansell, SM
    Colgan, JP
    Geyer, S
    Maurer, MJ
    Inwards, DJ
    White, WL
    Horning, SJ
    Habermann, TM
    BLOOD, 2003, 102 (11) : 643A - 644A
  • [37] Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
    Ho-Jin Shin
    Joo Seop Chung
    Moo-Kon Song
    Seon-Kyeong Kim
    Sangmin Choe
    Goon-Jae Cho
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1165 - 1172
  • [38] Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
    Shin, Ho-Jin
    Chung, Joo Seop
    Song, Moo-Kon
    Kim, Seon-Kyeong
    Choe, Sangmin
    Cho, Goon-Jae
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1165 - 1172
  • [39] CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
    Czuczman, MS
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 88 - 96
  • [40] Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy
    Kim, Seok Jin
    Lee, Seung Jin
    Choi, In Young
    Park, Yong
    Choi, Chul Won
    Kim, In Sun
    Yu, Woosung
    Hwang, Hee Sang
    Kim, Byung Soo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (03) : 177 - 184